Repligen Corp. 10-Q Summary: Quarter Ended December 31, 2003
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2003, and the nine-month period ended on that date. Repligen Corporation develops novel therapeutics for neuropsychiatric and immune disorders, including secretin for autism and CTLA4-Ig for autoimmune diseases. The company also generates revenue from specialty pharmaceutical products, specifically Protein A for the pharmaceutical industry and SecreFlo (synthetic porcine secretin) for diagnostic use.
Key Financial Metrics
| Metric | 3 Months Ended Dec 31, 2003 | 9 Months Ended Dec 31, 2003 |
|---|---|---|
| Total Revenue | $1,320,846 | $4,800,762 |
| Gross Profit | $538,613 (41% margin) | $2,422,469 (50% margin) |
| Net Loss | $(2,126,906) | $(6,294,904) |
| Net Loss Per Share (Basic/Diluted) | $(0.07) | $(0.21) |
| Cash and Cash Equivalents | $2,369,818 (as of Dec 31, 2003) | |
| Total Marketable Securities | $23,089,656 (Current + Long-term) | |
| Working Capital | $11,012,341 | |
| Total Debt | None reported |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 45% ($1.1M) for the quarter and 16% ($0.9M) for the nine-month period compared to the prior year. This was primarily driven by manufacturing problems at a significant customer purchasing Protein A products.
- Increased Operating Expenses: Operating expenses rose 27% ($0.6M) for the quarter and 37% ($2.5M) for the nine-month period. Research and Development (R&D) expenses increased 36% and 35% respectively, due to higher clinical trial and personnel costs.
- Widened Net Loss: The net loss for the quarter more than doubled to $2.1M from $0.8M in the prior year. The nine-month loss increased to $6.3M from $2.8M.
- Liquidity Position: Despite operating losses, total cash and marketable securities increased to approximately $25.7M from $18.9M at the start of the fiscal year, bolstered by a $11.8M net proceeds from a common stock issuance in May 2003.
Outlook, Risks, and Management Commentary
- Clinical Trial Failure: In January 2004, the company announced that its Phase 3 clinical trial for RG1068 (synthetic human secretin) for autism failed to show improvement over placebo in core social interaction symptoms. The company is analyzing data and discussing results with the FDA.
- License Termination: Repligen terminated its 1999 License Agreement with ChiRhoClin, the sole supplier of SecreFlo, due to ChiRhoClin's failure to meet obligations. Repligen seeks to recover $2.25M in cash and stock payments made previously through future royalties. There is a risk that ChiRhoClin may fail to continue supplying SecreFlo, restricting sales.
- Intellectual Property Litigation: Repligen is appealing a District Court ruling against its claim of inventorship regarding CTLA4-Ig patents held by Bristol-Myers Squibb. Failure to obtain these rights could restrict commercialization of CTLA4-Ig.
- Liquidity Outlook: Management believes current funding is sufficient for the next 24 months. However, future financing needs cannot be guaranteed on favorable terms.
Investor Verification Checklist
- Verify the status of the Phase 3 autism trial data analysis and FDA discussions following the negative results.
- Confirm the supply chain stability of SecreFlo following the termination of the ChiRhoClin agreement and the mechanism for royalty recovery.
- Monitor the progress of the appeal regarding the CTLA4-Ig patent litigation against Bristol-Myers Squibb.
- Assess the impact of the manufacturing issues at the major Protein A customer on future revenue projections.
- Review the burn rate relative to the $25.7M cash position to validate the 24-month liquidity runway.